ATRS 9/29/18 is the PDUFA date for its subcutaneous testosterone treatment Royalty revenues from AMAG's auto-injectable Makena should increase for mush of 2018. Otrexup and their auto-injectable migraine treatment continue to grow ANDAs for 3 TEVA-partnered generics have been submitted including an Epipen product that is a potential $500mn-plus opty. In their latest reported Q, net loss fell to $3.7mn with cash equaling $31.6mn * consider a run-up strategy after June earnings release.